A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder.
bipolar disorder
depression
dietary supplement
mania
mental health
neuroscience
nutraceuticals
psychiatry
Journal
Canadian journal of psychiatry. Revue canadienne de psychiatrie
ISSN: 1497-0015
Titre abrégé: Can J Psychiatry
Pays: United States
ID NLM: 7904187
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
pubmed:
24
9
2020
medline:
19
8
2021
entrez:
23
9
2020
Statut:
ppublish
Résumé
Certain nutrient supplements (nutraceuticals) may target neurobiological pathways perturbed in bipolar disorder (BD) such as inflammation, oxidative stress, and mitochondrial dysfunction. Nutraceuticals thus may have a potential role as adjunctive treatments for BD. A search of Embase via embase.com, PubMed via PubMed, Cumulated index to nursing and allied health literature (CINAHL) Complete via EBSCO, and Cochrane Central Register of Controlled Clinical Trials via cochranelibrary.com was conducted to identify published randomized controlled trials assessing the efficacy of nutraceuticals on mood symptomatology in adults with BD. Search terms for BD, nutraceuticals, and clinical trials (total search terms = 75) were used to search from inception to February 20, 2020. The Cochrane Collaboration's tool for assessing the risk of bias in randomized trials was used to assess the risk of bias. A total of 1,712 studies were identified through the search. After rigorous screening, 22 studies were included in the review. There was large variability across the studies with 15 different nutraceutical agents assessed and as such insufficient homogeneity for a meta-analysis to be conducted ( Given nutraceuticals are tolerable and accessible, they may be useful as potential adjunctive treatments for BD. Nutraceuticals targeting neuroinflammation or mitochondrial activity may have the most potential for the depressive phase. However, further studies are required to determine efficacy.
Sections du résumé
BACKGROUND
Certain nutrient supplements (nutraceuticals) may target neurobiological pathways perturbed in bipolar disorder (BD) such as inflammation, oxidative stress, and mitochondrial dysfunction. Nutraceuticals thus may have a potential role as adjunctive treatments for BD.
METHODS
A search of Embase via embase.com, PubMed via PubMed, Cumulated index to nursing and allied health literature (CINAHL) Complete via EBSCO, and Cochrane Central Register of Controlled Clinical Trials via cochranelibrary.com was conducted to identify published randomized controlled trials assessing the efficacy of nutraceuticals on mood symptomatology in adults with BD. Search terms for BD, nutraceuticals, and clinical trials (total search terms = 75) were used to search from inception to February 20, 2020. The Cochrane Collaboration's tool for assessing the risk of bias in randomized trials was used to assess the risk of bias.
RESULTS
A total of 1,712 studies were identified through the search. After rigorous screening, 22 studies were included in the review. There was large variability across the studies with 15 different nutraceutical agents assessed and as such insufficient homogeneity for a meta-analysis to be conducted (
CONCLUSION
Given nutraceuticals are tolerable and accessible, they may be useful as potential adjunctive treatments for BD. Nutraceuticals targeting neuroinflammation or mitochondrial activity may have the most potential for the depressive phase. However, further studies are required to determine efficacy.
Identifiants
pubmed: 32966097
doi: 10.1177/0706743720961734
pmc: PMC7958203
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
262-273Références
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Am J Psychiatry. 2016 Jun 1;173(6):575-87
pubmed: 27113121
Br J Psychiatry. 2006 Jan;188:46-50
pubmed: 16388069
J Clin Psychopharmacol. 2013 Oct;33(5):627-35
pubmed: 23948785
J Clin Psychopharmacol. 2018 Oct;38(5):460-466
pubmed: 30106880
Bipolar Disord. 2000 Mar;2(1):47-55
pubmed: 11254020
Iran J Psychiatry. 2020 Jan;15(1):10-16
pubmed: 32377210
Br J Psychiatry. 2003 Mar;182:210-3
pubmed: 12611783
Schizophr Res. 2018 Sep;199:395-402
pubmed: 29588126
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Psychother Psychosom. 2013;82(1):10-9
pubmed: 23147067
Psychopharmacology (Berl). 2002 Mar;160(2):192-7
pubmed: 11875637
Aust N Z J Psychiatry. 2013 Jun;47(6):564-8
pubmed: 23493756
Br J Psychiatry. 2001 Oct;179:356-60
pubmed: 11581118
Bipolar Disord. 2007 Dec;9(8):884-7
pubmed: 18076538
Biol Psychiatry. 2006 Nov 1;60(9):1020-2
pubmed: 16814257
J Clin Psychiatry. 2005 Dec;66(12):1613-4
pubmed: 16401167
Neurosci Biobehav Rev. 2017 Mar;74(Pt A):1-20
pubmed: 28093238
Aust N Z J Psychiatry. 2015 Dec;49(12):1087-206
pubmed: 26643054
Bipolar Disord. 2011 Aug-Sep;13(5-6):454-65
pubmed: 22017215
Biol Psychiatry. 2008 Sep 15;64(6):468-75
pubmed: 18534556
Lancet Psychiatry. 2016 Jan;3(1):31-39
pubmed: 26687300
J Affect Disord. 2019 Feb 15;245:1043-1051
pubmed: 30699846
J Affect Disord. 2019 Jun 1;252:334-349
pubmed: 30999090
J Clin Psychopharmacol. 2007 Oct;27(5):498-502
pubmed: 17873684
Biol Psychiatry. 1998 Feb 1;43(3):230-2
pubmed: 9494705
Acta Psychiatr Scand. 2009 Dec;120(6):441-5
pubmed: 19392814
Neurosci Biobehav Rev. 2016 Sep;68:694-713
pubmed: 27377693
Bipolar Disord. 2006 Apr;8(2):168-74
pubmed: 16542187
BMC Med. 2019 Jan 25;17(1):18
pubmed: 30678686
J Psychiatr Res. 2017 Dec;95:48-53
pubmed: 28777983
BMJ Open. 2019 Apr 4;9(4):e025640
pubmed: 30948585
AAPS PharmSci. 2003;5(3):E25
pubmed: 14621960
Br J Pharmacol. 2009 Dec;158(8):2014-21
pubmed: 19917061
Biol Psychiatry. 2008 Sep 1;64(5):361-8
pubmed: 18436195
J Clin Psychopharmacol. 2014 Jun;34(3):413-6
pubmed: 24699040
J Neural Transm (Vienna). 2018 Feb;125(2):247-257
pubmed: 29177955